A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Insulin glargine (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BRIGHT
- Sponsors Sanofi
- 04 Dec 2017 According to a Sanofi media release, company plans to provide full results in 2018.
- 04 Dec 2017 Primary endpoint (Change from baseline in HbA1c) has been met, according to a Sanofi media release.
- 21 Sep 2017 Status changed from active, no longer recruiting to completed.